Proactive monitoring of pediatric hemodialysis vascular access: Effects of ultrasound dilution on thrombosis rates  by Goldstein, Stuart L. et al.
Kidney International, Vol. 62 (2002), pp. 272–275
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Proactive monitoring of pediatric hemodialysis vascular access: nous fistula (AVF) or graft (AVG) is preferred over
Effects of ultrasound dilution on thrombosis rates. indwelling catheters, stenosis of the venous outflow tract
Background. Hemodialysis vascular access thrombosis
can lead to decreased access flow and increased recircula-(VAT) is a significant cause of morbidity for hemodialysis
tion, preclude delivery of adequate dialysis and predis-patients and results, in part, from decreased access flow poten-
tially caused by venous outflow stenosis. We have previously pose to vascular access thrombosis (VAT) [1–3].
shown ultrasound dilution (UD) to be a practical and reliable Ultrasound dilution (UD) is a simple, non-invasive
predictor of venous outflow in children receiving hemodialysis.
bedside test for monitoring vascular access flow (QA)Methods. The current study is the first to our knowledge to
for patients receiving hemodialysis. A month-to-monthassess the impact of a proactive UD monitoring program upon
VAT in pediatric patients. Nine patients experienced 18 VAT decrease in access flow of greater than 15% [4] or an
over the two-year study. Mean values for variables potentially absolute access flow of less than 650 mL/min [5] as mea-
associated with VAT were compared to values from a size-
sured by UD is associated with an increased risk of VATmatched seven patient group without VAT during the study
in adults. Prospective study using UD to monitor for aperiod. VAT rates were compared between the year-before
(pre-UD era) and year-after (UD era) UD was initiated. Dur- 20% decrease in vascular access flow or an absolute QA
ing the latter half of the UD era (rapid referral period), patients 600 mL/min to lead to prompt referral for angioplasty
with VA flow rate (QAcorr)650 mL/min/1.73 m2 were referred demonstrated decreased VAT rates in adult patients [6].for balloon angioplasty within 48 hours.
Another adult study demonstrated decreased VAT ratesResults. Mean QAcorr was lower for patients with subsequent
VAT (562 290 mL/min/1.73 m2) versus patients without VAT and dialysis unit cost when UD was used for referral to
(1005  372 mL/min/1.73 m2; P  0.02). The VAT rate was angioplasty [7].
significantly lower in the UD era (4.1 VAT/100 patient-months)
No published studies exist to our knowledge with re-versus the pre-UD era (11.0 VAT/100 patient-months; P 
spect to permanent vascular access monitoring in chil-0.03). The decrease in VAT rates was caused predominantly
in the rapid referral period, where the VAT rate dropped to dren. As a result of the dearth of data, the NKF-DOQI
0.96 VAT/100 patient-months (P  0.001). Cost of vascular Vascular Access Work Group could not make any rec-
access management was 65% higher ($1264 vs. $765/patient-
ommendations with respect to pediatric permanent vas-month) in the pre-UD era, reflecting the increased cost for
cular access management [8]. Recently, we showed UDtreatment of VAT.
Conclusions. Monthly QAcorr 650 mL/min/1.73 m2 is pre- to be a reliable predictor of venous stenosis in children
dictive of imminent VAT in children receiving hemodialysis. receiving hemodialysis [9]. Our study demonstrated that
Prompt referral for angioplasty of VA with QAcorr 650 mL/ if vascular access flow by UD was corrected for patientmin/1.73 m2 leads to decreased VAT rates in children.
size (QAcorr, mL/min/1.73 m2), a value 650 mL/min/1.73
m2 was both 100% sensitive and specific for venous steno-
sis 50% as measured by contrast venography.Provision of adequate hemodialysis depends upon a
We have been performing routine monthly UD moni-properly functioning hemodialysis vascular access. While
toring of QAcorr in all permanent vascular access in ourpermanent vascular access in the form of an arteriove-
pediatric hemodialysis unit since April 2000. The aims
of the current study were to determine if monthly UDKey words: childhood ESRD, venous stenosis, angioplasty, adequacy
of dialysis, arteriovenous grafts. measurement can decrease VAT rates by leading to ex-
peditious referral for angioplasty, and to assess the effect
Received for publication December 3, 2001
of proactive vascular access management practice usingand in revised form February 12, 2002
Accepted for publication February 14, 2002 UD on the cost of vascular access management in a
pediatric hemodialysis program. 2002 by the International Society of Nephrology
272
Goldstein et al: Proactive monitoring of pediatric HD vascular access 273
Table 1. Comparison of clinical variables for patientsMETHODS
with and without VAT
Monthly UD was performed prospectively (HD01plus
VAT No VAT PHemodialysis Monitor; Transonic Systems, Ithaca, NY,
Patient weight kg 47.814.6 45.510.0 NSUSA) to evaluate access flow in all children with an AVF
QAcorr mL/min/1.73 m2 562290 1005372 0.02or AVG who had been receiving chronic hemodialysis Double-pool Kt/V 1.220.18 1.220.14 NS
for at least two months in the Texas Children’s Hospital Abbreviations are: VAT, vascular access thrombosis; QAcorr, vascular access
flow rate; Kt/V, dialysis dose.Renal Dialysis Unit, Houston, Texas from April 2000 to
April 2001 (UD era). VAT rates, double-pool Kt/V, and
dialysis unit cost for providing vascular access manage-
ment were compared between the UD era and the imme-
ogist and radiology suite expenses). Adjustments werediate one year prior (pre-UD era) to when routine
made for item cost price increases over each fiscal yearmonthly UD measurement was instituted. Double-pool
during the study period. Cost data do not include theKt/V was estimated using the logarithmic extrapolation
one-time charge for UD equipment purchase. There aremethod of Goldstein and Brewer [10]. Kt/V measure-
no disposable costs associated with UD monitoring. Allments were performed within two weeks of UD measure-
cost data are reported based on an adjusted 2001 fiscalment. There were no technical problems that prohibited
year basis. Total cost data also were adjusted for patientroutine monthly UD measurement during the study pe-
census by dividing the total cost by the aggregate patientriod.
census for the pre-UD era (109 patient-months) and UDThe same nurse (A.A.) performed all UD measure-
era (147-patient months).ments during the first 60 minutes of the dialysis session.
The technique employs two reusable sensors one of each Statistical analysis
attached to the venous and arterial line while the patient
Potential associations between double pool Kt/V,is receiving hemodialysis. After the lines are temporarily
QAcorr and VAT were evaluated by independent t testreversed (to create recirculation), a 20 mL bolus of saline
comparing patients with VAT to a size-matched seven-
is injected quickly into the venous line. The sensors are
patient group without VAT during the study period. To
attached to a computer that interprets the changes in
determine if a decrease in double-pool Kt/V occurred
Doppler velocity as the hematocrit changes in relation
prior to VAT, monthly double-pool Kt/V changes were
to dialyzer blood flow. The manufacturer provided soft- recorded for the two months prior to VAT. We instituted
ware to adjust for caliber difference between adult and our policy of rapid referral for venogram with balloon
pediatric sized blood tubing. angioplasty for all accesses with QAcorr650 mL/min/1.73Ultrasound dilution reports access flow (QA) results m2 in November 2000. To determine the extent to which
in mL/min. To adjust for patient size, raw QA was cor- rapid referral contributed to the decrease in VAT during
rected for body surface area and reported as QAcorr in the UD era, VAT rates from April 2000 to November
mL/min/1.73 m2. After analysis of our previous UD data 2000 (pre-rapid referral) and from November 2000 to
up through November 2000 demonstrated QAcorr 650 April 2001 (rapid referral period) were examined sepa-
mL/min/1.73 m2 predicted 50% luminal stenosis with rately. Comparison of VAT rates (expressed as number
100% specificity and sensitivity, patients with QAcorr650 of VAT episodes per patient month) between the pre-
mL/min/1.73 m2 were referred for outpatient contrast UD era and UD era was performed using chi-square
venography performed by an interventional radiologist analysis. A P value 0.05 was considered significant.
at an adjacent adult care hospital. Patients with 50%
luminal stenosis received balloon angioplasty of the ste-
RESULTSnosis. To determine the effectiveness of balloon angio-
plasty on QAcorr, UD was performed during a hemodialy- Twenty-one patients received 222 UD measurements
sis treatment within one week after angioplasty. Patients during the UD era. Nine patients (mean weight 47.7 
with VAT underwent surgical thrombectomy performed 14.6 kg, range 23.7 to 69.2 kg) experienced 18 VAT
by a pediatric surgeon under general anesthesia at Texas episodes (7 AVG, 1 AVF) over the two-year course of
Children’s Hospital. study. Mean values for variables potentially associated
Cost data were available for all patients. The cost of with VAT were compared to values obtained in the same
providing vascular access management was compared month from a size-matched seven-patient group (mean
for the one year before (pre-UD era) and after (UD wt 45.4  9.6 kg, range 32 to 60 kg; 4 AVG, 3 AVF)
era) routine monthly UD measurement was instituted without a VAT during the study period.
as part of our practice. Cost data accounted for throm- Vascular access flow rate (QAcorr) was the only clinical
bectomy/access revision costs (operating room and hos- variable associated with subsequent development of
VAT in the following month (Table 1). Mean QAcorr waspital stay expenses) and balloon angioplasty cost (radiol-
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Table 2. Comparison of cost data between the pre-ultrasoundsignificantly lower for patients with subsequent VAT
dilution (pre-UD) and UD eras
(562  290 mL/min/1.73 m2) versus patients without
Pre-UD era UD EraVAT (1005  372 mL/min/1.73 m2; P  0.02).
1. Venogram/angioplasty total cost $ 23,055 34,039Since the majority of VAT occurred in AVG, the
2. Mean venogram/angioplasty cost peranalysis was repeated only for AVG. QAcorr in AVG was patient $/patient-month 212 232
lower for patients with subsequent VAT (562 290 mL/ 3. Total VAT treatment cost $ 114,619 78,454
Total VAT treatment OR cost $ 50,725 46,197min/1.73 m2) versus AVG without VAT (990  349 mL/
Total VAT treatment hospitalizationmin/1.73 m2), although the difference did not reach statis-
cost $ 63,894 32,257
tical significance (P  0.09). Once again, none of the 4. Mean VAT treatment cost per patient
$/patient-month 1,052 533other clinical variables demonstrated a statistically sig-
nificant difference between AVG with and without VAT. Overall total cost for vascular access
management $ (line 1  line 3) 137,674 112,493No difference in mean double-pool Kt/V (1.20  0.16
Overall mean cost per patient for VAvs. 1.22  0.16) was noted between the pre-UD era
management $/patient-month (line 2 
and the UD era. In addition, no difference was noted line 4) 1,264 765
between double-pool Kt/V for patients with VAT versus All cost data were adjusted for inflation and reported in fiscal 2001 terms.
Mean cost per patient was determined by dividing total cost by patient censuspatients without VAT (1.22 0.18 vs. 1.22 0.14). Mean
during the pre-UD era (109 patient-months) and the UD era (147 patient-double-pool Kt/V did not differ for vascular accesses with months).
QAcorr values lower or higher than 650 mL/min/1.73 m2.
The mean change in double-pool Kt/V from the two
months prior to VAT was 0.03  0.13 (range 0.42
to 0.30). The mean percent change double-pool Kt/V era versus $232/patient-month for the UD era. Total
costs adjusted for inflation for treatment of VAT, includ-from the two months prior to VAT was 2.3%  9.8%
(27.6 to 22.9%). Sixty percent of patients had a de- ing hospitalization, were $114,619 for the pre-UD era
crease in Kt/V in the two months prior to VAT. and $78,454 for the UD era, respectively. When adjusted
All but one patient with VAT had a preceding monthly for patient census, the VAT treatment cost was $1052/
QAcorr 650 mL/min/1.73 m2. The other patient had an patient-month for the UD era versus $533/patient-month
episode of severe dehydration that preceded his VAT for the UD era. Total cost for vascular access manage-
event. ment (angiography, operating room and hospitalization
The unit VAT rate was significantly lower in the UD- expense) was $1264/patient-month in the pre-UD era
era (6 thromboses in 147 patient-months, 4.1 thrombo- and $765/patient-month in the UD era, respectively. Cost
ses/100 patient-months) versus the pre-UD era (12 data are listed in Table 2.
thromboses in 109 patient-months, 11.0 thromboses/100
patient-months; P  0.03). After November 2000, we
DISCUSSIONinstituted a policy of referral within 48 hours for contrast
Provision of adequate hemodialysis depends upon avenography with possible angioplasty for all accesses
properly functioning vascular access. Vascular accesswith QAcorr 650 mL/min/1.73 m2. We observed a VAT
morbidity costs total nearly $8,000 per patient-year inrate of 9.8/100 patient-months in the pre-rapid referral
the adult hemodialysis patient population [8]. A recentperiod. The VAT rate in the rapid referral period (0.96/
adult study demonstrated decreased VAT rates and mor-100 patient-months) was significantly lower than the
bidity for patients who received monthly access monitor-rates observed in both the pre-UD era (P  0.001) and
ing by UD versus static venous pressure monitoring orthe pre-rapid referral period (P  0.02) of the UD era.
no monitoring at all [6]. Pediatric patients have smallerThirteen patients received 28 surveillance venograms
vessel sizes and could theoretically be higher risk forin the pre-UD period during which 13 angioplasty proce-
venous stenosis and VAT. We have previously demon-dures were performed for50% luminal stenosis. Seven
strated the reliability of UD in predicting venous stenosispatients received 8 angioplasty procedures for QAcorr
in our pediatric hemodialysis population [9]. The current650 mL/min/1.73 m2 during the UD era. Angioplasty
study evaluates the effect of a prospective vascular accessresulted in a significant improvement in QAcorr from 393
monitoring program on VAT rates and cost of vascular155 to 850  215 mL/min/1.73 m2 (P  0.001) in the UD
access management in children and adolescents.era. No patient in either era developed a VAT in the
Institution of UD monitoring was associated with amonth following angioplasty.
significant decrease in VAT rates (11.0/100 patient-Cost data were available for all patients during the
months to 4.1/100 patient-months) over the entire studystudy period. Total venogram/angioplasty costs adjusted
period. Further examination of the UD era revealedfor inflation were $23,055 for the pre-UD era and $34,039
the decrease in VAT rates was made predominantly byfor the UD era. Venogram/angioplasty cost adjusted for
patient census was $212/patient month in the pre-UD combining UD with rapid referral to angioplasty. Prompt
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referral for angioplasty within 48 hours of monthly QAcorr when QAcorr 650 mL/min/1.73 m2 led to only a minor
increase in venogram/angioplasty cost. A far greater in-650 mL/min/1.73 m2 resulted in a significant decrease
in VAT rates (11 VAT/100 patient-months to 0.96 VAT/ crease in the UD era venogram/angioplasty cost might
have been predicted, since UD could conceivably lead100 patient-months). The data suggest the decrease in
VAT rates resulted from balloon angioplasty, since sig- to more angioplasty procedures. The minor increase in
observed venogram/angioplasty cost might result fromnificant improvement in QAcorr was observed in the week
after the angioplasty procedure. Prior to the use of the ability of UD to predict accesses at-risk for stenosis
and help avoid unnecessary surveillance venography ofmonthly UD measurement, our center screened for
access stenosis using a surveillance venography proto- well-functioning accesses.
Since we were comparing annual costs for vascularcol. Well functioning accesses were screened every six
months, while accesses with a history of previous stenosis access management, which are costs that are expected
to recur each year, we elected not to incorporate thewere screened every 6 to 12 weeks. While extremely
accurate in detecting stenosis, this invasive surveillance one-time cost for purchase of the UD monitor in the
current analysis. The manufacturer’s list price is $12,330.venography protocol was associated with a 10 times
greater VAT rate than a protocol of monthly non-inva- In the current study, the total annual cost savings were
$25,181, which is nearly double the list price of the UDsive UD monitoring and rapid referral for angioplasty
when QAcorr 650 mL/min/1.73 m2. monitor. There are no disposable items necessary to
perform the UD procedure.Decreasing clearance as measured by Kt/V has been
advocated as a screening measure for poorly functioning The results of the current study support the use of
monthly vascular access monitoring by UD and foraccesses, since venous stenosis can lead to access recircu-
lation and a reduction in Kt/V. The current data demon- prompt referral for balloon angioplasty when QAcorr650
mL/min/1. 73 m2. Such practice lead to a decreased pa-strated no difference in double-pool Kt/V between ac-
cesses with QAcorr values lower or higher than 650 mL/ tient morbidity and pediatric dialysis unit cost during the
time period studied. Further long-term study is needed tomin/1.73 m2 or patients with and without VAT. Further-
more, 40% of patients actually had an increase in double determine if such a proactive vascular access manage-
ment program will result in prolonged AVG and AVFpool Kt/V in the two months prior to VAT. These data
suggest that Kt/V may be neither a sensitive nor specific survival in children receiving hemodialysis.
indicator of venous stenosis.
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